Premorbid negative symptoms in first-episode psychosis

European Journal of Psychiatry

Volumn 21, Issue 3, 2007, Pages 220-229

  Cuesta, Manuel J ^a   Peralta, Victor ^a   Gil, Patxi ^b   Artamendi, Maria ^b  

^a Universidad Pública de Navarra   (Spain)

^b Vasque Health System Osakidetza   (Spain)

Author keywords

First episode Pychosis; Negative symptoms; Neuropletic na ve patients; Premorbid personality; Residual symptoms; Schizophrenia

Indexed keywords

ADULT; AGED; ARTICLE; BRIEF PSYCHOTIC DISORDER; CONTROLLED STUDY; DELUSIONAL DISORDER; DEPRESSION; DISORIENTATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MENTAL DISEASE; NEGATIVE SYNDROME; PERSONALITY TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SYMPTOMATOLOGY;

EID: 37749043253     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632007000300007     Document Type: Article

References (29)

1. Kiberstis P, Roberts L. It's not just the genes. Science 2002; 296: 685.
2. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002; 31: 285-293.
3. Fanous AH, Kendler KS. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry 2005;10: 6-13.
4. Rodríguez-Solano JJ, Gonzalez-de-Chavez M. Premorbid personality disorders in schizophrenia. Schizophr Res 2000; 44: 137-44.
5. Keshavan MS, Duggal HS, Veeragandham G, McLaughlin NM, Montrose DM, et al. Schooler NE. Personality dimensions in first-episode psychoses. Am J Psychiatry 2005; 162: 102-109.
6. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 2000; 45: 191-201.
7. Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994; 11: 11-20.
8. Flaum M, Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry 1995; 36: 421-427.
9. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 2000; 157: 1461-1466.
10. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985; 11: 440-452.
11. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45-49.
12. Möller HJ, Müller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 1997; 247: 1-5.
13. Kelley ME, van Kammen DP, Allen DN. Empirical validation of primary negative symptoms: indepedence from effects of medication and psychosis. Am J Psychiatry 1999; 156: 406-411.
14. McCreadie RG, Connolly MA, Williamson DJ, Athawes RWB, Tilak-Sihgh D. The Nithsdale Schizophrenia Surveys. XII. Neurodevelopmental schizophrenia: A search for clinical correlates and putative aetiological factors. Br J Psychiatry 1994; 165: 340-346.
15. Baum KM, Walker E, Childhood behavioral patterns of adult symptom dimensions in schizophrenia. Schizophrenia Res 1995; 16: 111-120.
16. Cannon TD, Mednick SA, Parnas J. Antecedents of predominantly negative and predominantly positive symptom schizophrenia in a high risk population. Arch Gen Psychiatry 1990; 47: 622-632.
17. Jorgensen A., Parnas J. The Copenhagen high-risk study: premorbid and clinical dimensions of maternal schizophrenia. J Nerv Ment Dis 1990; 178: 370-376.
18. Cuesta, MJ, Peralta V, Caro F. Premorbid personality in psychoses. Schizophr Bull 1999; 25: 801-811.
19. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 1994; 53: 31-40.
20. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID): I. history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624-629.
21. American Psychiatric Association.: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994.
22. Cuesta MJ, Gil P, Artamendi M, Serrano JF, Peralta V. Premorbid personality and psychopathological dimensions in first-episode psychosis. Schizophr Res 2002; 58: 273-280.
23. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-546.
24. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Special 1970; 212: 11-19.
25. Tyrer P. Personality disorder. Diagnosis, management and course. London: Wright, 1988.
26. van Mastrigt S, Addington J. Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. J Psychiatry Neurosci 2002; 27: 92-101.
27. Yung AR, Phillips LJ, Yuen, HP, McGorry, PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142.
28. Faraone SV, Green AI, Seidman LJ, Tsuang MT. Schizotaxia: clinical implications and new directions for research. Schizophr Bull 2001; 27: 1-18.
29. Owens DG, Miller P, Lawrie SM, Johnstone EC. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry 2005; 186: 386-393.